Literature DB >> 33368252

Acute Δ9-tetrahydrocannabinol prompts rapid changes in cannabinoid CB1 receptor immunolabeling and subcellular structure in CA1 hippocampus of young adult male mice.

Itziar Bonilla-Del Río1,2, Nagore Puente1,2, Amaia Mimenza1,2, Almudena Ramos1,2, Maitane Serrano1,2, Leire Lekunberri1,2, Inmaculada Gerrikagoitia1,2, Brian R Christie3,4,5, Patrick C Nahirney3,4,5, Pedro Grandes1,2,3.   

Abstract

The use and abuse of cannabis can be associated with significant pathophysiology, however, it remains unclear whether (1) acute administration of Δ-9-tetrahydrocannabinol (THC) during early adulthood alters the cannabinoid type 1 (CB1 ) receptor localization and expression in cells of the brain, and (2) THC produces structural brain changes. Here we use electron microscopy and a highly sensitive pre-embedding immunogold method to examine CB1 receptors in the hippocampus cornu ammonis subfield 1 (CA1) 30 min after male mice were exposed to a single THC injection (5 mg/kg). The findings show that acute exposure to THC can significantly decrease the percentage of CB1 receptor immunopositive terminals making symmetric synapses, mitochondria, and astrocytes. The percentage of CB1 receptor-labeled terminals forming asymmetric synapses was unaffected. Lastly, CB1 receptor expression was significantly lower at terminals of symmetric and asymmetric synapses as well as in mitochondria. Structurally, CA1 dendrites were significantly larger, and contained more spines and mitochondria following acute THC administration. The area of the dendritic spines, synaptic terminals, mitochondria, and astrocytes decreased significantly following acute THC exposure. Altogether, these results indicate that even a single THC exposure can have a significant impact on CB1 receptor expression, and can alter CA1 ultrastructure, within 30 min of drug exposure. These changes may contribute to the behavioral alterations experienced by young individuals shortly after cannabis intoxication.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  RRID: MGI:3831871; RRID: MGI:5658455; THC; addiction; endocannabinoid system; hippocampus; immunoelectron microscopy

Mesh:

Substances:

Year:  2021        PMID: 33368252     DOI: 10.1002/cne.25098

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  5 in total

1.  Axonal CB1 Receptors Mediate Inhibitory Bouton Formation via cAMP Increase and PKA.

Authors:  Jian Liang; Dennis L H Kruijssen; Aniek C J Verschuuren; Bas J B Voesenek; Feline F W Benavides; Maria Sáez Gonzalez; Marvin Ruiter; Corette J Wierenga
Journal:  J Neurosci       Date:  2021-08-19       Impact factor: 6.167

2.  GLAST versus GFAP as astroglial marker for the subcellular study of cannabinoid CB1 receptors in astrocytes.

Authors:  Svein Achicallende; Itziar Bonilla-Del Río; Maitane Serrano; Amaia Mimenza; Leire Lekunberri; Ilazki Anaut-Lusar; Nagore Puente; Inmaculada Gerrikagoitia; Pedro Grandes
Journal:  Histochem Cell Biol       Date:  2022-07-19       Impact factor: 2.531

3.  Knockout of Dopamine D3 Receptor Gene Blocked Methamphetamine-Induced Distinct Changes of Dopaminergic and Glutamatergic Synapse in the Nucleus Accumbens Shell of Mice.

Authors:  Shuai Wang; Ming Li; Linlan Su; Yu Wang; Dongliang Ma; Hongyan Wang; Jie Zhu; Teng Chen
Journal:  Front Cell Neurosci       Date:  2022-05-30       Impact factor: 6.147

4.  Acute Delta 9-tetrahydrocannabinol administration differentially alters the hippocampal opioid system in adult female and male rats.

Authors:  Kyle A Windisch; Sanoara Mazid; Megan A Johnson; Elina Ashirova; Yan Zhou; Lennox Gergoire; Sydney Warwick; Bruce S McEwen; Mary Jeanne Kreek; Teresa A Milner
Journal:  Synapse       Date:  2021-10       Impact factor: 2.537

Review 5.  The Endocannabinoid System in Glial Cells and Their Profitable Interactions to Treat Epilepsy: Evidence from Animal Models.

Authors:  Jon Egaña-Huguet; Edgar Soria-Gómez; Pedro Grandes
Journal:  Int J Mol Sci       Date:  2021-12-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.